keyword
MENU ▼
Read by QxMD icon Read
search

Psma

keyword
https://www.readbyqxmd.com/read/29455299/prostate-specific-membrane-antigen-in-breast-cancer-a-comprehensive-evaluation-of-expression-and-a-case-report-of-radionuclide-therapy
#1
Yuri Tolkach, Heidrun Gevensleben, Ralph Bundschuh, Aydan Koyun, Daniela Huber, Christina Kehrer, Thomas Hecking, Mignon-Denise Keyver-Paik, Christina Kaiser, Hojjat Ahmadzadehfar, Markus Essler, Walther Kuhn, Glen Kristiansen
PURPOSE: Prostate-specific membrane antigen (PSMA), a protein product of the folate hydrolase 1 (FOLH1) gene, is gaining increasing acceptance as a target for positron emission tomography/computer tomography (PET/CT) imaging in patients with several cancer types, including breast cancer. So far, PSMA expression in breast cancer endothelia has not been sufficiently characterized. METHODS: This study comprised 315 cases of invasive carcinoma of no special type (NST) and lobular breast cancer (median follow-up time 9...
February 17, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29454548/correlation-between-molecular-tumor-volume-evaluated-with-68-ga-psma-pet-ct-and-prostatic-specific-antigen-levels
#2
S Medina-Ornelas Sevastián, O García-Pérez Francisco, Y Hernández-Pedro Norma, E Arellano-Zarate Angélica, L Abúndiz-López Blanca
OBJECTIVE: To investigate the association between prostatic-specific antigen (PSA) levels and molecular tumor volume (MTV) measured in the68 Ga-PSMA PET/CT, both done in a short period of time, in prostate cancer patients with biochemical failure. METHODS: Eighty-four patients who underwent68 Ga-PSMA PET/CT and measurement of PSA levels in the same week (trigger-PSA) were studied in this retrospective analysis. MTV was calculated from the sum of the metastatic lesions...
February 14, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29445927/advantage-of-18-f-psma-1007-over-68-ga-psma-11-pet-imaging-for-differentiation-of-local-recurrence-vs-urinary-tracer-excretion
#3
Kambiz Rahbar, Matthias Weckesser, Hojjat Ahmadzadehfar, Michael Schäfers, Lars Stegger, Martin Bögemann
No abstract text is available yet for this article.
February 14, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29439481/review-of-gallium-68-psma-pet-ct-imaging-in-the-management-of-prostate-cancer
#4
REVIEW
Nat P Lenzo, Danielle Meyrick, J Harvey Turner
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by 68 Ga-PSMA-positron emission tomography/computed tomography ( 68 Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to have superseded CT, and appears superior to MR imaging, for the detection of metastatic disease. 68 Ga-PSMA PET/CT has the ability to reliably stage prostate cancer at presentation and can help inform an optimal treatment approach...
February 11, 2018: Diagnostics
https://www.readbyqxmd.com/read/29439016/psma-targeted-radionuclide-therapy-and-salivary-gland-toxicity-why-does-it-matter
#5
David Taïeb, Jean-Marc Foletti, Manuel Bardiès, Palma Rocchi, Rodney Hicks, Uwe Haberkorn
No abstract text is available yet for this article.
February 9, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29434370/imaging-predicting-68ga-psma-pet-ct-positivity-for-recurrent-disease
#6
Louise Stone
No abstract text is available yet for this article.
February 13, 2018: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29432341/rare-case-of-intratracheal-metastasis-detected-on-68ga-prostate-specific-membrane-antigen-pet-ct-scan-in-a-case-of-thyroglobulin-elevated-negative-iodine-scan-syndrome
#7
Arun Sasikumar, Ajith Joy, M R A Pillai, Karuna Elza Oommen, R Jayakumar
A 64-year-old woman underwent completion thyroidectomy with upper tracheal ring resection and right-sided neck dissection for papillary carcinoma of the thyroid infiltrating the trachea and was given I radioiodine treatment. Three years later, she presented with hemoptysis. On evaluation, she had increased serum thyroglobulin and negative iodine scan (TENIS). F-FDG PET/CT scan did not identify any site of disease. One year later, Ga-PSMA scan done revealed a moderate focal tracer-avid intratracheal soft tissue; biopsy revealed it to be metastatic papillary carcinoma of the thyroid...
February 9, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29430118/penile-metastasis-from-prostate-cancer-presenting-as-malignant-priapism-detected-using-gallium-68-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography
#8
Koramadai Karuppusamy Kamaleshwaran, Barani Kumar Pollachi Balasundararaj, Raghi Jose, Ajit Sugunan Shinto
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (Ga-68 PSMA PET/CT) is a promising diagnostic tool for patients with prostate cancer. Penile metastasis from prostate cancer is a rare phenomenon that infrequently manifests as malignant priapism. We present a case of 79-year-old patient diagnosed as a case of adenocarcinoma prostate presenting with penile metastases imaged using Ga-68 PSMA PET/CT.
January 2018: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/29426963/prostate-specific-membrane-antigen-psma-expression-in-breast-cancer-and-its-metastases
#9
Mariz Kasoha, Clara Unger, Erich-Franz Solomayer, Rainer M Bohle, Claudia Zaharia, Fadi Khreich, Stefan Wagenpfeil, Ingolf Juhasz-Böss
The present study was undertaken to investigate the expression of prostate-specific membrane antigen (PSMA) in normal breast tissues, in cancerous breast tissues and in distant metastases from patients with breast cancer. Immunohistochemical analysis was performed to determine PSMA expression and angiogenic activity using anti-PSMA mAb and anti-CD31 mAb respectively. Immunofluorescence staining was applied to confirm the exact co-localization of PSMA and CD31. We observed different patterns of PSMA expression between normal and cancerous tissues...
February 10, 2018: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/29422356/will-68ga-psma-radioligands-be-the-only-choice-for-nuclear-medicine-in-prostate-cancer-in-the-near-future-a-clinical-update
#10
V Cuccurullo, G D di Stasio, L Evangelista, A Ciarmiello, L Mansi
Prostate Cancer (PCa) represents the most common malignant tumor in men but according to the European Association of Urology (EAU) guidelines, a mass screening for PCa diagnosis should not be performed due to over-diagnosis and over-treatment related problems. An early clinical diagnosis is possible, mainly based on digital rectal examination and Prostatic Specific Agent (PSA) testing. However, the only mandatory test to define the presence of PCa is ultrasound guided-biopsy, obtained on multiple samples, which has also a high prognostic value...
February 5, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29419479/the-effect-of-total-tumor-volume-on-the-biologically-effective-dose-of-tumor-and-kidneys-for-177lu-labelled-psma-peptides
#11
Nusrat Begum, Anne Thieme, Nina Eberhardt, Robert Tauber, Ambros J Beer, Gerhard Glatting, Matthias Eiber, Peter Kletting
Aim: To simulate the effect of PSMA positive total tumor volume (TTV) on the tumor and organs at risk (OARs) biologically effective doses (BEDs) in patients with metastatic castration resistant prostate cancer (mCRPC) in 177Lu-PSMA radioligand therapy. Methods: A physiologically-based pharmacokinetic model was fitted to data of 13 patients treated with 177Lu-PSMA I&T. The tumor, kidneys and salivary glands BEDs were simulated for TTVs of 0.1-10 l. The activity and peptide amounts leading to an optimal tumor-to-kidneys BED ratio were also investigated...
February 1, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29419475/biochemical-recurrence-of-prostate-cancer-initial-results-with-18f-psma-1007-pet-ct
#12
Frederik Giesel, Leon Will, Claudia Kesch, Martin Freitag, Christophe Kremer, Jonas Merkle, Oliver Neels, Jens Cardinale, Boris Hadaschik, Markus Hohenfellner, Klaus Kopka, Uwe Haberkorn, Clemens Kratochwil
Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68Ga-labelled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labelled ligands were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent positron emission tomography/computed tomography (PET/CT) scans 1h and 3h after injection (p...
February 1, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29411076/solitary-testicular-metastasis-from-prostate-cancer-a-case-report-diagnosed-by-pet-ct-with-psma
#13
Marcelo Livorsi da Cunha, Camila de Oliveira Rodrigues, Mariana Petruccelli Lima de Araújo, Celso Heitor de Freitas Junior, Robson Ferrigno
No abstract text is available yet for this article.
February 6, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29409824/68ga-psma-pet-ct-for-primary-diagnosis-of-prostate-cancer-in-men-with-contraindications-to-or-negative-mpmri-a-prospective-observational-study
#14
Egesta Lopci, Alberto Saita, Massimo Lazzeri, Giovanni Lughezzani, Piergiuseppe Colombo, Nicolò Maria Buffi, Rodolfo Hurle, Katia Marzo, Roberto Peschechera, Alessio Benetti, Silvia Zandegiacomo, Luisa Pasini, Giuliana Lista, Pasquale Cardone, Angelo Castello, Davide Maffei, Luca Balzarini, Arturo Chiti, Giorgio Guazzoni, Paolo Casale
BACKGROUND: 68Ga-PSMA PET/CT may represent the most promising imaging modality for identification and risk stratification of prostate cancer (PCa) in patients with contraindications to or negative multiparametric MRI (mpMRI). METHODS: This prospective observational study analyzed 68Ga-PSMA PET/CT in a selected group of patients with persistently elevated PSA and/or PHI (prostate health index) suspicious for PCa, negative digital rectal examination, and at least one negative biopsy...
January 31, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29402740/synthesis-of-novel-multivalent-fluorescent-inhibitors-with-high-affinity-to-prostate-cancer-and-their-biological-evaluation
#15
Young-Do Kwon, Hea-Jong Chung, Sun Joo Lee, Sun-Hwa Lee, Byung-Hoon Jeong, Hee-Kwon Kim
Prostate-specific membrane antigen (PSMA) is an important biological target for therapy and diagnosis of prostate cancer. In this study, novel multivalent PSMA inhibitors with glutamate-urea-lysine structures were designed to improve inhibition characteristics. Precursors of the novel inhibitors were prepared from glutamic acid with di-tert-butyl ester. A near-infrared molecular dye, sulfo-Cy5.5, was introduced into the precursors to generate the final PSMA fluorescent inhibitors, compounds 12-14, to visualize prostate cancer...
January 31, 2018: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/29401152/prostate-specific-membrane-antigen-pet-ct-incidental-finding-of-a-schwannoma
#16
André H Dias, Kirsten Bouchelouche
We describe a case of a 73-year-old man with newly diagnosed prostate cancer referred to Ga-PSMA PET/CT for staging. A focal uptake of PSMA was visualized in the prostate compatible with primary prostate cancer. Outside the prostate, a PSMA-avid paravertebral soft tissue mass was observed. Further investigation with MRI of the same region showed signs compatible with schwannoma. This case shows the importance of including schwannoma in the differential diagnostic evaluation of patients with Ga-PSMA-positive foci in paravertebral locations, as schwannomas may show avid PSMA uptake and may potentially lead to an incorrect diagnosis of metastasis...
February 3, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29401151/spect-ct-with-the-psma-ligand-99mtc-mip-1404-for-whole-body-primary-staging-of-patients-with-prostate-cancer
#17
Christian Schmidkonz, Michael Cordes, Michael Beck, Theresa Ida Goetz, Daniela Schmidt, Olaf Prante, Tobias Bäuerle, Michael Uder, Bernd Wullich, Peter Goebell, Torsten Kuwert, Philipp Ritt
BACKGROUND: Tc-MIP-1404 (Progenics Pharmaceuticals, Inc, New York, NY) is a novel ligand binding to prostate-specific membrane antigen suitable for SPECT. There are, as yet, no data concerning its use in whole-body primary staging and its interobserver variability in patients with prostate cancer (PC) prior to therapy. METHODS: A search of our clinical database from April 2013 to May 2017 yielded 93 patients with histologically confirmed cancer in whom Tc-MIP-1404 SPECT/CT had been performed for primary whole-body staging before therapy...
February 3, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29401150/68ga-prostate-specific-membrane-antigen-expression-in-neurocysticercosis-lesions-in-a-patient-with-prostate-carcinoma
#18
Shelvin Kumar Vadi, Rajender Kumar, Harmandeep Singh, Shrawan Kumar Singh, Bhagwant Rai Mittal
Ga-prostate-specific membrane antigen (PSMA) ligand is a well-known tracer used in prostate cancer. Nevertheless, there are reports of unusual Ga-PSMA uptake in variety of benign lesions. We report a case of prostate cancer in which Ga-PSMA PET/CT revealed tracer avidity in the enhancing walls of cystic lesions in the brain consistent with the features of neurocysticercosis. The uptake of Ga-PSMA in neurocysticercosis is not known and may be attributed to angiogenesis occurring at the periphery of these lesions...
February 3, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29401146/177lu-prostate-specific-membrane-antigen-super-scan-and-good-response-even-after-1-cycle-of-radioligand-therapy
#19
Kamran Aryana, Soroush Zarehparvar Moghadam, Roham Salek, Ghasemali Divband
A 76-year-old man with castration-resistant prostate cancer and widespread skeletal metastases underwent 2 cycles of Lu-prostate-specific membrane antigen (PSMA) 617 therapy in our department. Whole-body Lu-PSMA scan after the first cycle showed diffuse skeletal PSMA-avid lesions, whereas no PSMA uptake was evident in the kidneys with minimal PSMA uptake by salivary glands (super scan). After 6 weeks, he received the second dose of Lu-PSMA and whole-body scan after the treatment showed remarkable resolution of skeletal metastases and normal PSMA uptake by the kidneys and salivary glands...
February 3, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29400475/albumin-binding-psma-ligands-optimization-of-the-tissue-distribution-profile
#20
Martina Benešová, Christoph A Umbricht, Roger Schibli, Cristina Müller
The prostate-specific membrane antigen (PSMA) has emerged as an attractive prostate cancer associated target for radiotheragnostic application using PSMA-specific radioligands. The aim of this study was to design new PSMA ligands modified with an albumin-binding moiety in order to optimize their tissue distribution profile. The compounds were prepared by conjugation of a urea-based PSMA-binding entity, a DOTA chelator, and 4-(p-iodophenyl)butyric acid using multistep solid phase synthesis. The three ligands (PSMA-ALB-02, PSMA-ALB-05, and PSMA-ALB-07) were designed with varying linker entities...
February 5, 2018: Molecular Pharmaceutics
keyword
keyword
5864
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"